Close
Close

Celator Pharmaceuticals - Secondary AML

Partner

Not provided

Rare Disease

Secondary AML

Sponsor

Celator Pharmaceuticals

Access Program Information

This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.

Contact

Contact: Arthur C Louie, MD (6092430123)

Locations
  • United States
  • Los Angeles, California, United States
  • United States
  • Atlanta, Georgia, United States
  • United States
  • Chicago, Illinois, United States
  • United States
  • Indianapolis, Indiana, United States
  • United States
  • Kansas City, Kansas, United States
  • United States
  • New York, New York, United States

Free Newsletter